Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm lowered their price objective on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

Shares of APVO stock opened at $0.16 on Monday. The firm has a fifty day simple moving average of $0.28 and a 200-day simple moving average of $0.68. Aptevo Therapeutics has a twelve month low of $0.14 and a twelve month high of $16.57.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.26. As a group, equities analysts predict that Aptevo Therapeutics will post -2.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.